Skip to content

Collection of Blood for Gene Expression/Genomic Studies in Individuals With Diabetes (Qatar)

Collection of Blood for Gene Expression/Genomic Studies in Individuals With Diabetes (Qatar)

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01172743
Enrollment
450
Registered
2010-07-30
Start date
2009-06-30
Completion date
2020-07-31
Last updated
2020-07-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Type 2 Diabetes Mellitus

Keywords

Diabetes Mellitus, Diabetes, Type-2, Adult Onset

Brief summary

This protocol is designed to gather a small amount of blood for extraction of DNA for the study of the genetic basis of diabetes. The study population will include individuals with known diabetes, and controls without diabetes. Investigators aim to understand the genetics of diabetes, and will use the cells and serum from this blood to perform genotyping and gene expression studies of individuals with diabetes and relevant controls.

Detailed description

This protocol is designed to collect a small amount of blood for extraction of DNA (genetic material) for the study of the genetic basis of diabetes. The study population will include individuals with known diabetes and controls without diabetes. Additionally, this protocol will recruit individuals from the following locations: the Qatar Diabetes Association, the governmental ministries of Qatar, and subjects who have participated in Dr. Bener's HMC protocol #231 entitled A preliminary study of genetic pre-disposition to diabetic mellitus in the state of Qatar. Individuals with diabetes may also be recruited from the Hamad Hospital outpatient adult diabetes clinics (there are eight diabetes clinics each week) and/or from the population of subjects who previously participated in Dr. Mushlin's IRB approved protocol #0608008703 entitled Comparing the Clinical Management and Genetic Markers of Diabetes in Qatar to International Standards at Hamad Medical Corporation or IRB approved protocol #0602008388 entitled The Impact of Cardiac and Genetic Risk Factors on Acute Myocardial Infarction and Cerebrovascular Stroke in Qatar: A Case-Control Study. In this protocol, researchers will survey medical records of patients with diabetes, in order to study the clinical characteristics of these individuals, and the researchers will collect blood to evaluate the genetic characteristics of individuals with diabetes. The researchers will also collect blood samples of individuals without diabetes to serve as control.

Interventions

None listed

Sponsors

Weill Cornell Medical College in Qatar
CollaboratorOTHER
Hamad Medical Corporation
CollaboratorINDUSTRY
Weill Medical College of Cornell University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
Yes

Inclusion criteria

Diabetes group Inclusion criteria: * Must provide informed consent * Males and females, age 18 years and older * Documented evidence of diabetes using at least one of the following: (1) blood tests consistent with Type-II diabetes; (2) oral glucose tolerance tests consistent with Type-II diabetes; (3) subject taking medication to treat Type-II diabetes.

Exclusion criteria

* Individual refuses consent * Pregnant females with gestational diabetes * Type-I diabetes Normal control group Inclusion Criteria: * Must provide informed consent * Males or females ages 18 years and older * Resolved gestational diabetes

Countries

Qatar

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026